最近的前列腺癌药物治疗方面的进展
Kotaro Suzuki1, Naohiro Fujimoto2, Masaki Shiota3
1Division of Urology, Kobe University Graduate School of Medicine, 7-5-1 Kusunoki-Cho, Chuo-Ku, Kobe, Hyogo, 650-0017, Japan. pikataro1012@gmail.com.
Japanese journal of radiology
|June 18, 2025
概括
最近的进展改善了转移性前列腺癌 (PCa) 的存活率. 然而,复杂的治疗策略和积极的PCa变体,如神经内分泌PCa (NEPC) 存在持续的临床挑战.
科学领域:
- 在瘤学瘤学.
- 泌尿器科 泌尿器科 泌尿器科 泌尿器科
- 医学指导方针 医学指导方针
背景情况:
- 由于雄激素受体信号抑制剂 (ARSI),化疗,PARPi和PSMA放射性体治疗,转移性前列腺癌 (PCa) 的存活率有所改善.
- 像成像和基因组测试这样的先进诊断工具已经重塑了PCa管理.
- 对于非转移性抵抗割的前列腺癌 (nmCRPC) 和与治疗相关的神经内分泌PCa (t-NEPC) 等侵略性变体的新疾病概念使治疗策略复杂化.
研究的目的:
- 审查目前日本晚期前列腺癌的药物治疗策略.
- 为解决晚期前列腺癌管理中的临床问题.
- 与2023年日本前列腺癌临床实践指南保持一致.
主要方法:
- 关于PCa治疗近期进展的文献综述.
- 对新出现的PCa变异及其临床影响的分析.
- 基于2023年日本前列腺癌临床实践指南的数据综合.
主要成果:
- 在过去二十年中,转移性PCa的生存结果有所改善.
- 由于众多的药物选择,治疗选择的复杂性增加.
- 包括t-NEPC在内的侵袭性PCa变体的出现是一个重大的临床问题.
结论:
- 先进的前列腺癌管理需要导航复杂的治疗景观.
- 解决像t-NEPC这样的攻击性PCa变体至关重要.
- 遵守最新的临床指南对于最佳的患者护理至关重要.
相关概念视频
Targeted Cancer Therapies
7.8K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.8K
Combination Therapies and Personalized Medicine
5.1K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.1K
Cancer Vaccines
520
Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
520
Treatment Resistant Cancers
3.4K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
260
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
260
Cancer Therapies
8.0K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
8.0K


